NLSP Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -- compared to NLS Pharmaceutics's net margin of -2841.85%. NLS Pharmaceutics's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.

NLS Pharmaceutics has a consensus price target of --, signalling upside risk potential of 10566.67%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 239.75%. Given that NLS Pharmaceutics has higher upside potential than Addex Therapeutics, analysts believe NLS Pharmaceutics is more attractive than Addex Therapeutics.

NLS Pharmaceutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.646, suggesting its more volatile than the S&P 500 by 64.6%.

NLS Pharmaceutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NLS Pharmaceutics pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

NLS Pharmaceutics quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. NLS Pharmaceutics's net income of -- is lower than Addex Therapeutics's net income of -$1.6M. Notably, NLS Pharmaceutics's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is 1.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NLS Pharmaceutics is -- versus 24.16x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -- compared to NLS Pharmaceutics's net margin of -106.6%. NLS Pharmaceutics's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -18.65%.

NLS Pharmaceutics has a consensus price target of --, signalling upside risk potential of 10566.67%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.80 which suggests that it could grow by 48.34%. Given that NLS Pharmaceutics has higher upside potential than CRISPR Therapeutics AG, analysts believe NLS Pharmaceutics is more attractive than CRISPR Therapeutics AG.

NLS Pharmaceutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.822, suggesting its more volatile than the S&P 500 by 82.156%.

NLS Pharmaceutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NLS Pharmaceutics pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

NLS Pharmaceutics quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. NLS Pharmaceutics's net income of -- is lower than CRISPR Therapeutics AG's net income of -$136M. Notably, NLS Pharmaceutics's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NLS Pharmaceutics is -- versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Molecular Partners AG has a net margin of -- compared to NLS Pharmaceutics's net margin of -2408.81%. NLS Pharmaceutics's return on equity of -- beat Molecular Partners AG's return on equity of -37.36%.

NLS Pharmaceutics has a consensus price target of --, signalling upside risk potential of 10566.67%. On the other hand Molecular Partners AG has an analysts' consensus of $10.85 which suggests that it could grow by 197.38%. Given that NLS Pharmaceutics has higher upside potential than Molecular Partners AG, analysts believe NLS Pharmaceutics is more attractive than Molecular Partners AG.

NLS Pharmaceutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NLS Pharmaceutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NLS Pharmaceutics pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.

NLS Pharmaceutics quarterly revenues are --, which are smaller than Molecular Partners AG quarterly revenues of $787.5K. NLS Pharmaceutics's net income of -- is lower than Molecular Partners AG's net income of -$18.6M. Notably, NLS Pharmaceutics's price-to-earnings ratio is -- while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NLS Pharmaceutics is -- versus 18.81x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines has a net margin of -- compared to NLS Pharmaceutics's net margin of 0.11%. NLS Pharmaceutics's return on equity of -- beat BeOne Medicines's return on equity of -11.54%.

NLS Pharmaceutics has a consensus price target of --, signalling upside risk potential of 10566.67%. On the other hand BeOne Medicines has an analysts' consensus of $332.60 which suggests that it could grow by 19.14%. Given that NLS Pharmaceutics has higher upside potential than BeOne Medicines, analysts believe NLS Pharmaceutics is more attractive than BeOne Medicines.

NLS Pharmaceutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.282, suggesting its less volatile than the S&P 500 by 71.823%.

NLS Pharmaceutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NLS Pharmaceutics pays -- of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend.

NLS Pharmaceutics quarterly revenues are --, which are smaller than BeOne Medicines quarterly revenues of $1.1B. NLS Pharmaceutics's net income of -- is lower than BeOne Medicines's net income of $1.3M. Notably, NLS Pharmaceutics's price-to-earnings ratio is -- while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NLS Pharmaceutics is -- versus 7.17x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.